Avandia Hearing Soap Opera: Ethics, Demagogy, Sensationalism, and Threats by GSK

Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.

We accept advertising relevant to the interests of our members.
For more information, see:

Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com

My Humble Opinion	Other People's Opinion
A "Must Read" Blog for Insiders. -- Wall Street Journal	A bi-weekly podcast. Listen and call-in live online or download to your iPod!

| Also see Pharma Marketing News OpEd Pieces |

Avandia Hearing Soap Opera: Ethics, Demagogy, Sensationalism, and Threats by GSK

Posted: June 6, 2007

Almost as soon as Dr. Nissen began his testimony today before Congressman Waxman's Committee on Oversight and Government Reform, he commented that the Committee's work was "clearly the right thing to do."

Rep. Darrell E. Issa (R-California), on the other hand, clearly considered the Committee's work a political circus. Another congressman called it "sensationalism."

But Dr. John B. Buse, a nationally noted diabetes specialist, took center stage with his revelations about how he was treated by GSK several years ago after warning the FDA about Avandia's cardiovaascular problems.

For more, see this post to Pharma Marketing Blog.

For more posts in related topic areas, see:

Drug Safety

If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.

| Return to Pharma Marketing Blog Topics |

Special Supplement
Direct-to-Consumer Advertising
Volume Two: DTC in the New Era

DTC advertising is set for major changes in light of public criticism, but also in reaction to the changing reality of the marketplace where there is less need for a one size fits all solution. DTC must evolve and marketers must pay more attention to measuring and improving its effectiveness. Otherwise, billions of dollars will continue to be wasted. This volume is devoted to DTC best practices with a focus on techniques for improving DTC efficacy and return on investment, which is generally considered to be declining.

TABLE OF CONTENTS

Order both Volume One and Volume Two and SAVE! (Click Here)

Order and pay for Volume Two now using your credit card.

ONLY $29.95
PDF file delivered to you by email (usually within minutes of placing your order):

If you wish to be pay by check or credit card off-line, please use:
Printable Order Form